Agenus Inc. AGEN
6.73 USD -0.14 (-2.04%)
Regular-session close
6.73 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
6.50 Day range 6.97
2.77 52-week range 9.93
- YTD
- +114.33%
- 1 year
- +55.43%
News
benzinga.com B. Riley Securities Reiterates Buy on Agenus, Raises Price Target to $16 B. Riley Securities analyst Mayank Mamtani reiterates Agenus (NASDAQ:AGEN) with a Buy and raises the price target from $14 to $16.
seekingalpha.com Agenus Inc. (AGEN) Discusses BOT BAL Development and Planned Phase 3 ROBBIN Trial Transcript Agenus Inc. ( AGEN ) Discusses BOT BAL Development and Planned Phase 3 ROBBIN Trial November 5, 2026 11:30 AM EST Company Participants Zack Armen - Vice President of Investor Relations & Corporate…
zacks.com Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down AGEN's Q3 earnings meet estimates, but a revenue miss weighs on shares as pipeline progress, Armenian drug approvals and new funding emerge as key developments.
benzinga.com Agenus Announces New Findings From Long-Term Survivor Analysis Of Phase 1b C-800-01 Trial Evaluating Botensilimab In Combination With Balstilimab In Heavily Pretreated Patients With MSS, mCRC Without Active Liver Metastases Long-term survival of patients in the 123-patient Phase 1b CRC cohort was not limited to patients with favorable baseline characteristics, suggesting durable benefit may extend across a broader…
businesswire.com Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026 LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new findings from a long-term survivor analysis of its…
marketbeat.com Agenus Targets Phase 3 Colon Cancer Trial as Financing Hinges on Enrollment Milestones Agenus NASDAQ: AGEN expects to begin enrolling patients in the next few months for a Phase 3 trial of its investigational immunotherapy combination BOT/BAL in early-stage colon cancer, executives…
benzinga.com Agenus Q3 Sales $31.500M Beat $28.217M Estimate Agenus (NASDAQ:AGEN) reported quarterly sales of $31.500 million which beat the analyst consensus estimate of $28.217 million by 11.64 percent. This is a 4.30 percent increase over sales of $30.200…
businesswire.com Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Armenia--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the third quarter ended September 30,…
businesswire.com Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #IO--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Chief Commercial Officer, and Zack Armen, Vice…
businesswire.com Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the…
gurufocus.com Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026 [url="]Agenus Inc. (Nasdaq: AGEN)[/url], a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR)
businesswire.com Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026 LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR)…
businesswire.com Agenus to Provide Third Quarter 2026 Financial Report and Development Update LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026…
marketbeat.com Agenus Pivots BOT/BAL Strategy to Phase III Colon Cancer Trial Agenus NASDAQ: AGEN is concentrating its registration strategy for BOT/BAL on the Phase III ROBBIN trial in neoadjuvant high-risk stage II and III microsatellite-stable (MSS) colon cancer, after…
defenseworld.net Agenus Inc. (NASDAQ:AGEN) Stock Has Consensus Price Target of $24.50 According to Analysts Agenus Inc. (NASDAQ: AGEN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six research firms that are currently covering the stock, Marketbeat reports. One…
businesswire.com Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Zack Armen, Head of Corporate Development and…
benzinga.com Agenus Receives Marketion Authorization From Armenia For Botvymo To Treat Adult Patients With Microsatellite Stable Metastatic Colorectal Cancer Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo®…
businesswire.com Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Armenia--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has…
defenseworld.net ImageneBio (NASDAQ:IMA) and Agenus (NASDAQ:AGEN) Critical Survey ImageneBio (NASDAQ: IMA - Get Free Report) and Agenus (NASDAQ: AGEN - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses…
defenseworld.net Agenus (NASDAQ:AGEN) Stock Keeps “Buy” Rating at Chardan Capital Agenus (NASDAQ: AGEN - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at Chardan Capital in a research report issued on Monday, Benzinga reports. They…
benzinga.com Reported Saturday, Agenus Says 25% Of Recurrent Ovarian Cancer Patients Treated With BOT+BAL Were Alive And Off All Therapy At Last Follow-Up, With 48% Estimated Three-Year Survival Among Evaluable Patients Survival estimate remained at 48% between years two and three, extending evidence of durable benefitResults observed in heavily pretreated, difficult-to-treat population that received a median of…
gurufocus.com Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 [url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of
businesswire.com Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of…
gurufocus.com Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026 [url="]Agenus Inc.[/url] (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), a- benzinga.com Agenus To Present Research On Botensilimab, Fc-Enhanced Multifunctional Anti-CTLA-4 Antibody, In Combination With Balstilimab, Anti-PD-1 Antibody, At SITC 2026 Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody,…
businesswire.com Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026 LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an…
benzinga.com Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.- benzinga.com Rodman & Renshaw Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $19 Rodman & Renshaw analyst Michael King initiates coverage on Agenus (NASDAQ:AGEN) with a Buy rating and announces Price Target of $19.
- benzinga.com Chardan Capital Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $40 Chardan Capital analyst Andreas Argyrides initiates coverage on Agenus (NASDAQ:AGEN) with a Buy rating and announces Price Target of $40.
- benzinga.com Agenus’ NEST Phase 2 Results Published In Clinical Cancer Research, No Colorectal Cancer Recurrences Observed At Updated Median Follow-Up Of 32.2 Months In NEST-1 And 23.5 Months In NEST-2 In pMMR/MSS Tumors, Neoadjuvant BOT+BAL Achieved 59% Pathologic Response, Including 41% Major Pathologic Response And 32% Pathologic Complete Response No colorectal cancer recurrences observed at updated median follow-up of 32.2 months in NEST-1 and 23.5 months in NEST-2In pMMR/MSS tumors, neoadjuvant BOT+BAL achieved 59% pathologic response,…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Coty Posts Mixed Q4 Results, Joins Wolfspeed, ATRenew And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures mixed, Nasdaq 100 up 0.1%. Coty Inc (COTY) shares down 7.7% after reporting losses in Q4 and exit of Gucci Beauty license.
benzinga.com HC Wainwright & Co. Maintains Buy on Agenus, Lowers Price Target to $25 HC Wainwright & Co. analyst Emily Bodnar maintains Agenus (NASDAQ:AGEN) with a Buy and lowers the price target from $30 to $25.
benzinga.com Agenus Q2 Sales $34.500M Beat $34.000M Estimate Agenus (NASDAQ:AGEN) reported quarterly sales of $34.500 million which beat the analyst consensus estimate of $34.000 million by 1.47 percent. This is a 34.24 percent increase over sales of $25.700…
benzinga.com B. Riley Securities Maintains Buy on Agenus, Raises Price Target to $14 B. Riley Securities analyst Mayank Mamtani maintains Agenus (NASDAQ:AGEN) with a Buy and raises the price target from $8 to $14.
benzinga.com Why Is Agenus Stock Falling on Tuesday? Agenus Inc. (AGEN) stock experiences profit-taking on Tuesday after a 111% surge. Discover the latest clinical data and analyst updates.
benzinga.com Stock Market Today: Dow, S&P 500, Nasdaq 100 Futures Rise on Better-Than-Expected CPI Data—Tower Semiconductor, Twin Vee, JPMorgan In Focus (UPDATED) U.S. stock futures were mixed on Tuesday, as the Nasdaq 100 index advanced, while the Dow Jones and S&P 500 indices fell.
benzinga.com Oracle, Twin Vee PowerCats, Agenus, Micron Technology and SanDisk: Why These 5 Stocks Are on Investors' Radars Today ORCL, VEEE, AGEN, MU, SNDK were among the stocks seen trending on Monday, July 13, 2026.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session. The market value of their outstanding shares is at $139.5 million. Q32 Bio (NASDAQ:QTTB) stock rose…
benzinga.com Crude Oil Surges Over 5%; Twin Vee Powercats Shares Jump US stocks dip, Nasdaq falls 1%. Dow down 0.34%. Energy shares up 2.1%, tech down 1.2%. Micron Tech drops 5%. Commodities mixed. European and Asian markets close mixed.- benzinga.com HC Wainwright & Co. Maintains Buy on Agenus, Raises Price Target to $30 HC Wainwright & Co. analyst Emily Bodnar maintains Agenus (NASDAQ:AGEN) with a Buy and raises the price target from $23 to $30.
benzinga.com Why Is Agenus Stock Gaining Monday? Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M financing deal.
benzinga.com Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN Agenus stock surged 100%, after the biotech secured up to $340 million in fresh capital, extended its cash runway, shelving the Phase 3 BATTMAN trial while doubling down on ROBBIN.
benzinga.com US Stocks Mixed; Dow Gains Over 100 Points US stocks mixed, Dow up 100 points. Energy up 2.1%, tech down 1.1%. LogProstyle Inc shares rise on earnings. Oil up 3.9%, gold down 1%.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-market session. The company's market cap stands at $25.1 million. Q32 Bio (NASDAQ:QTTB) stock rose 65.92% to…- benzinga.com Market-Moving News for July 13th QTTB: 82% | Q32 Bio shares are trading higher after the company it will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial on Monday, July 13, 2026. AGEN: 36% |…
benzinga.com Agenus To Raise $85M To Fund Colon Cancer Drug Trial, Financing Could Reach $340M If Warrants Are Exercised Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in…- benzinga.com Agenus Presents 3-Yr Landmark Phase 1b Data From Fully Enrolled C-800-01 Cohort Evaluating Botensilimab Plus Balstilimab In Patients With Refractory MSS mCRC Without Active Liver Metastases At ESMO GI 2026 Fully enrolled 123-patient Phase 1b cohort demonstrated 21.2-month median overall survival, 33% three-year overall survival, and a survival curve plateau beyond two yearsData presented in a heavily…
- benzinga.com Agenus To Present 3-Yr Survival Data From Phase 1b C-800-01 Study Of Botensilimab Plus Balstilimab In Patients With Microsatellite Stable mCRC Without Active Liver Metastases At ESMO GI 2026 Data reflect an additional year of follow-up from the 123-patient cohort in the Phase 1b studyAgenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that three-year…
- benzinga.com Agenus Reports Durable Survival And Deep Responses With Botensilimab Plus Balstilimab In Heavily Pretreated Checkpoint-Resistant Melanoma, Including 16.6-Month Median OS and 42% Two-Year Survival First presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resisted prior checkpoint therapy and who had poor-risk disease featuresIn the overall BOT+BAL treated…